Using Circulating Tumor Cell Counts to Guide Extra Chemotherapy in Oral Cavity Cancer
Tests low-dose oral chemotherapy guided by tumor cell counts in people after oral cancer treatment.
Plain-language title generated from the registry record
Registry title: Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
Key facts
- Where
- Taoyuan City, TaiwanSee the site
Where in Taiwan
- Linkou Chang-Gung Memorial HospitalTaoyuan City, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT07296250
- Record updated
- 22 December 2025
- Original description
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.Read full original descriptionShow less
A Randomized, Prospective Phase II Clinical Trial - Extended Chemotherapy or Not Based on Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Completing Adjuvant Concurrent Chemoradiotherapy
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.
Inclusion: Participants with Cancer:; Aged between 18 and 90 years; Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC); Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy; Willing to continue follow-up visits at the hospital after completion of treatment.
Exclusion: Presence of psychiatric disorders; Deemed unsuitable for participation by the attending physician; Unwilling to participate in the study.